Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
8-19-2020

Long term survival and local control outcomes from single dose
targeted intraoperative radiotherapy during lumpectomy (TARGITIORT) for early breast cancer: TARGIT-A randomised clinical trial.
Jayant S Vaidya
Max Bulsara
Michael Baum
Frederik Wenz
Samuele Massarut
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
See next page for additional authors
Part of the Oncology Commons

Recommended Citation
Vaidya, Jayant S; Bulsara, Max; Baum, Michael; Wenz, Frederik; Massarut, Samuele; Pigorsch, Steffi;
Alvarado, Michael; Douek, Michael; Saunders, Christobel; Flyger, Henrik L; Eiermann, Wolfgang; BrewGraves, Chris; Williams, Norman R; Potyka, Ingrid; Roberts, Nicholas; Bernstein, Marcelle; Brown, Douglas;
Sperk, Elena; Laws, Siobhan; Sütterlin, Marc; Corica, Tammy; Lundgren, Steinar; Holmes, Dennis R; Vinante,
Lorenzo; Bozza, Fernando; Pazos, Montserrat; Le Blanc-Onfroy, Magali; Gruber, Günther; Polkowski,
Wojciech; Dedes, Konstantin J; Niewald, Marcus; Blohmer, Jens; McCready, David; Hoefer, Richard;
Kelemen, Pond; Petralia, Gloria; Falzon, Mary; Joseph, David J; and Tobias, Jeffrey S, "Long term survival
and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy
(TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial." (2020). Articles, Abstracts, and
Reports. 3660.
https://digitalcommons.psjhealth.org/publications/3660

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St.
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.

Authors
Jayant S Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael
Alvarado, Michael Douek, Christobel Saunders, Henrik L Flyger, Wolfgang Eiermann, Chris Brew-Graves,
Norman R Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk,
Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis R Holmes, Lorenzo Vinante,
Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski,
Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen,
Gloria Petralia, Mary Falzon, David J Joseph, and Jeffrey S Tobias

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/3660

10/21/2020

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT)…

BMJ. 2020; 370: m2836.
Published online 2020 Aug 19.

PMCID: PMC7500441
PMID: 32816842

doi: 10.1136/bmj.m2836: 10.1136/bmj.m2836

Long term survival and local control outcomes from single dose
targeted intraoperative radiotherapy during lumpectomy (TARGITIORT) for early breast cancer: TARGIT-A randomised clinical trial
Jayant S Vaidya, professor of surgery and oncology,1 Max Bulsara, professor of biostatistics,2 Michael Baum,
professor emeritus of surgery,1 Frederik Wenz, professor of radiation oncology,3 Samuele Massarut, director,4
Steffi Pigorsch, consultant radiation oncologist,5 Michael Alvarado, professor of surgery,6 Michael Douek, professor
of surgical sciences and breast cancer,7 Christobel Saunders, professor of surgical oncology,8 Henrik L Flyger,
head,9 Wolfgang Eiermann, professor of gynaecological oncology and surgery,5 Chris Brew-Graves, director of
operations,1 Norman R Williams, deputy director,1 Ingrid Potyka, senior clinical operations manager,1
Nicholas Roberts, trial coordinator,1 Marcelle Bernstein, patient advocate,10 Douglas Brown, consultant breast
surgeon,11 Elena Sperk, associate professor of radiation oncology,3 Siobhan Laws, consultant oncoplastic
surgeon,12 Marc Sütterlin, professor of surgery and gynaecology,13 Tammy Corica, clinical research coordinator,14
Steinar Lundgren, professor,15 ,16 Dennis Holmes, consultant breast surgeon,17 Lorenzo Vinante, consultant
radiation oncologist,18 Fernando Bozza, consultant surgeon,19 Montserrat Pazos, consultant radiation
oncologist,20 Magali Le Blanc-Onfroy, consultant radiation oncologist,21 Günther Gruber, consultant radiation
oncologist,22 Wojciech Polkowski, professor of surgery,23 Konstantin J Dedes, consultant breast surgeon,24
Marcus Niewald, professor of radiation oncology,25 Jens Blohmer, professor of surgery and gynaecology,26
David McCready, consultant surgeon,27 Richard Hoefer, consultant surgeon,28 Pond Kelemen, clinical associate
professor of surgery,29 Gloria Petralia, consultant surgeon,30 Mary Falzon, consultant pathologist,31
David J Joseph, professor of radiation oncology,14 and Jeffrey S Tobias, professor of radiation oncology
1Division of Surgery and Interventional Science, University College London, 43-45 Foley Street, London W1W 7JN,

UK
2Department of Biostatistics, University of Notre Dame, Fremantle, WA, Australia
3Department of Radiation Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg

University, Heidelberg, Germany
4Department of Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
5Department of Gynaecology and Obstetrics, Red Cross Hospital, Technical University of Munich, Munich,

Germany
6Department of Surgery, University of California, San Francisco, CA, USA
7Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
8School of Surgery, University of Western Australia, Crawley, WA, Australia
9Department of Breast Surgery, University of Copenhagen, Copenhagen, Denmark
10London, UK
11Department of Surgery, Ninewells Hospital, Dundee, UK
12Department of Surgery, Royal Hampshire County Hospital, Winchester, UK
13Department of Gynaecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty Mannheim,

Heidelberg University, Heidelberg, Germany
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable

1/34

10/21/2020

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT)…
14

Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia

15

Department of Oncology, St Olav’s University Hospital, Trondheim, Norway

16

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim,

Norway
17

University of Southern California, John Wayne Cancer Institute & Helen Rey Breast Cancer Foundation, Los

Angeles, CA, USA
18

Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy

19

Instituto Oncologico Veneto, Padoa, Italy

20

Department of Radiation Oncology, University Hospital, The Ludwig Maximilian University of Munich, Munich,

Germany
21

Radiotherapy-Oncology, Western Cancer Institute, Nantes, France

22

Breast Centre Seefeld, Zurich, Switzerland

23

Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland

24

Breast Centre, University Hospital Zurich, Zurich, Switzerland

25

Saarland University Medical Center, Homberg, Germany

26

Sankt Gertrauden Hospital, Charité, Medical University of Berlin, Berlin, Germany

27

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

28

Sentara Surgery Specialists, Hampton, VA, USA

29

Ashikari Breast Center, New York Medical College, New York, NY, USA

30

Department of Surgery, University College London Hospitals, London, UK

31

Department of Pathology, University College London Hospitals, London, UK

31

Department of Clinical Oncology, University College London Hospitals, London, UK

Correspondence to: J S Vaidya jayantvaidya@gmail.com (or @jsvaidya on Twitter)
Accepted 2020 Jun 17.
Copyright © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See
rights and permissions. Published by BMJ.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC
BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

Abstract
Objective
To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during
lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast
cancer.
Design
Prospective, open label, randomised controlled clinical trial.
Setting
32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada.
Participants
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2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1,
eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre)
to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy
(EBRT).
Interventions
Random allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to
six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given
immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients
(around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found
unsuspected higher risk factors (around 20% of patients).
Main outcome measures
Non-inferiority with a margin of 2.5% for the absolute difference between the five year local recurrence
rates of the two arms, and long term survival outcomes.
Results
Between 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to
EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up
was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence
interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v
11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long
term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically
significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence
interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.82), distant disease-free
survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer
mortality (1.12, 0.63 to 1.28, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to
0.86, P=0.005).
Conclusion
For patients with early breast cancer who met our trial selection criteria, risk adapted immediate single
dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term
efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with
eligible patients when breast conserving surgery is planned.
Trial registration
ISRCTN34086741, NCT00983684.

Introduction
In 2018, two million patients were diagnosed as having breast cancer worldwide and 626 000 patients died
from the disease.1 Treatment with breast conserving surgery and adjuvant radiotherapy rather than total
mastectomy is suitable for most patients. Most local recurrences occur close to the primary tumour site
despite the frequent presence of microscopic cancer foci in other quadrants.2 3 Based on the hypothesis
that adjuvant radiotherapy for women with early breast cancer could be limited to the tumour bed and
given immediately during breast conserving surgery (lumpectomy), we developed the concept of targeted
intraoperative radiotherapy (TARGIT-IORT).4 5 6 7 When the TARGIT-A trial protocol was published in
1999,8 restricting radiotherapy to only the area around the tumour had been explored in small patient
9

10
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series9 and one randomised trial,10 which had reported inferior results. At that time whole breast
radiotherapy was the standard of care, and it remains so today, despite the publication of our initial
results11 12 13 and several other approaches.14 15 16 17 18 19 20 21
TARGIT-IORT provides a well positioned and rapid form of tumour bed irradiation focused on the target
tissues alone, while sparing normal tissues and organs such as heart, lung, skin, and chest wall structures.22
We designed the TARGIT-A randomised trial to compare risk adapted TARGIT-IORT with conventional
whole breast external beam radiotherapy (EBRT) over several weeks.4 11 13 The study received ethics
approval from the Joint University College London and University College London Hospital committees
of ethics of human research. Recruitment began in March 2000 and was completed in June 2012.
In 2004, four years after recruitment began for the main TARGIT-A trial and at the request of centres with
potentially high numbers of patients, we sought additional ethics approval and opened a parallel study.
This study was previously referred to as the post-pathology stratum and recruited 1153 patients by using a
separate randomisation table. These patients were randomised after their initial surgery to have either
conventional fractionated whole breast radiotherapy (n=572) or a further operation to deliver delayed
radiotherapy to the wound by reopening the original incision (n=581). The trial was initiated mainly
because of easier scheduling of delayed TARGIT-IORT in operating theatres. This delayed radiotherapy
was not intraoperative radiotherapy given during the cancer operation; treatment was performed a median
of 37 days after the first excision. The 2013 analysis found that this delayed second procedure crossed the
2.5% margin of non-inferiority. Therefore, we recommended that immediate TARGIT-IORT should be the
preferred treatment over delayed TARGIT-IORT,13 and delayed treatment was no longer used. As
specified in the statistical analysis plan, which was signed off before unblinding for this analysis, we have
addressed the long term outcomes for this parallel trial in a separate paper.
This paper reports the findings of the TARGIT-A trial, in which 2298 patients were randomised after their
needle biopsy and before any surgical excision of the cancer to receive either risk adapted TARGIT-IORT
delivered during the initial excision of cancer or postoperative whole breast external beam radiotherapy
(EBRT). We investigated whether immediate TARGIT-IORT was non-inferior to EBRT at five year
complete follow-up in terms of local recurrence, and also compared their long term survival outcomes.

Methods
TARGIT-A was a pragmatic, prospective, international, multicentre, open label, randomised, phase III trial
that compared risk adapted TARGIT-IORT with the conventional treatment of whole breast EBRT. The
trial protocol (https://njl-admin.nihr.ac.uk/document/download/2006598), including details of sample size
calculations and the random allocation process, has been previously described.11 13 In brief, women with
early breast cancer were eligible if they were aged 45 years or older, diagnosed by needle biopsy, and
suitable for wide local excision of invasive ductal carcinoma that was unifocal on conventional
examination and imaging (cT1 and small cT2 ≤3.5 cm, cN0-N1, M0, as confirmed by cytology or
histology). Breast magnetic resonance imaging was not required and only 5.6% of patients in the trial had
a scan.
Eligible patients were randomly assigned before their surgery (in a 1:1 ratio) to receive either a risk
adapted approach that used single dose TARGIT-IORT or EBRT according to standard schedules over
several weeks, with randomisation blocks stratified by centre. The randomisation schedules were generated
centrally by computer (securely kept in trial centres in Perth for Australian centres and London, United
Kingdom, for all other centres). Requests for randomisation were through telephone or fax to the trial
office (Perth or London), where a trained member of staff checked patient eligibility. Treatment was
allocated from a preprinted randomisation schedule available to authorised staff only. Written confirmation
of randomisation was sent by fax to the site.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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All patients gave written informed consent and needed to be available for regular follow-up for at least 10
years. Follow-up clinical examination was at least six monthly for the first five years and annually
thereafter, including a mammogram once a year.
The experimental arm was risk adapted radiotherapy. If the final pathology report showed prespecified
unpredicted features, EBRT was recommended in addition to TARGIT-IORT, with TARGIT-IORT (already
received during surgery) serving as the tumour bed boost. In the core protocol, EBRT was recommended to
supplement TARGIT-IORT within the experimental arm if the tumour-free margin was less than 1 mm, if
there was an extensive in situ component (>25%), or if unexpected invasive lobular carcinoma was found
in the postoperative final microscopic histopathological examination of the primary tumour excision.
Additionally, individual centres prespecified any other final postoperative histopathology criteria (such as
grade 3 tumour, node positivity, lymphovascular invasion) that would prompt supplemental EBRT to be
recommended. These criteria were recorded in the centre’s treatment policy document before their trial
recruitment started.
The trial was a comparison of two policies: whole breast radiotherapy without selection versus
individualised risk adapted radiotherapy; a proportion of patients who received TARGIT-IORT were also
given supplemental EBRT by using prespecified criteria. These patients were not crossovers, but were
offered individualised risk adapted radiotherapy according to the experimental treatment policy, which was
designed to reflect the real world scenario.
The TARGIT-IORT technique using the Intrabeam device (Carl Zeiss Meditec, Oberkochen, Germany)5 6
7
enables a patient to potentially receive all the required radiation in a single treatment under the same
anaesthetic as the primary surgery (efig 1).5 6 7 23 24 25 26 Radiation is delivered from a point source of 50
kV energy x rays at the centre of a spherical applicator over 20-50 minutes. The appropriately sized (1.5-5
cm diameter) applicator is surgically positioned in the tumour bed so that breast tissues at risk of local
recurrence receive the prescribed dose while skin and other organs are protected. The surface of the
tumour bed typically receives 20 Gy that attenuates to 5-7 Gy at 1 cm depth. Further details and a video
are available online (www.targit.org.uk; https://goo.gl/iuF9ZR). The patients in the conventional arm
underwent standard EBRT which always included fractionated whole breast radiotherapy for three to six
weeks, with or without an EBRT tumour bed boost, as determined by local criteria prespecified by the
collaborating centre.
We designed the trial as a non-inferiority trial. Non-inferiority trials in cancer are performed to test new
treatments that have obvious non-oncological advantages, such as better access, convenience, or quality of
life for the patient, or reduced costs for the healthcare system. The non-inferiority statistical test for such a
comparison is not meant to check for superiority, but to assess if the difference is within an acceptable
margin and the experimental treatment is not meaningfully worse than the control. Therefore, whether the
difference seen between the two randomised arms is statistically significant is not relevant here. As long as
the absolute difference is not clinically significant, the new treatment would be deemed non-inferior.27
Any chosen non-inferiority margin must be one that clinicians and patients agree is an acceptable
difference for the sake of the other benefits. These benefits might include lower toxicity, better cosmetic
outcome, better quality of life, and overall patient preference. Therefore, in the original protocol, noninferiority was specified as being achieved if the difference in the binomial proportions of local recurrence
rate at five years did not cross a stringent margin of 2.5% in absolute terms; that is, local recurrence risk
with TARGIT-IORT minus local recurrence risk with EBRT should not be more than 0.025 (2.5%). In the
2013 analysis, an even more rigorous criterion was used, specifying that the upper 90% confidence interval
of the absolute difference must not exceed 0.025 (2.5%).
The 2.5% non-inferiority margin in the TARGIT-A trial is a relevant, relatively stringent margin. Patient
preference studies in the United States, Australia, and Europe suggest that 2.5% is an acceptable margin.28
29 30 Importantly, it is widely regarded as a safe margin because it is well established that a local
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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recurrence difference of less than 10% at five years does not worsen breast cancer survival31; that is, when
the risk in arm A minus the risk in arm B is less than 0.1 (10%). A large increase in local recurrences
(>10% at five years) is required to lead to increased mortality because they can be effectively treated. For
example, a 20% increase in local recurrence (a risk increase by 0.2) would cause a 5% increase in deaths (a
mortality risk increase by 0.05)31; this was the basis for the ethics approval of this trial. In the ELIOT trial,
which also investigated intraoperative radiotherapy, the non-inferiority margin was set at 7%.15 In recently
reported trials of systemic therapy, the margin of a 3% difference in disease-free survival was considered
acceptable.32
Analysis of conventional longer term outcomes in breast cancer trials needs to include deaths as events for
two reasons. Firstly, deaths are one of the most important clinical outcomes. Secondly, longer follow-up in
an older population with early breast cancer means that death becomes much more common than local
recurrence. Importantly, if toxicity of treatment leads to a difference in mortality then it needs to be
reflected in the results. The statistical analysis plan for this long term analysis was signed off by the chair
of the independent steering committee and an independent senior statistician before the unblinded data
were sent to the trial statistician for the current analysis. The plan specified the primary outcome was local
recurrence-free survival. This outcome is consistent with the DATECAN33 and STEEP34 guidelines for
clinical events to be included in the definitions of time-to-event end points in randomised clinical trials
assessing treatments for breast cancer. Local recurrence-free survival is clinically meaningful because it
measures the chance of a patient being alive without local recurrence. Therefore, this outcome includes
local recurrence or death as events; that is, patients who had died were not censored. Clinicians and
patients need to know the chance of being alive without a local recurrence, which is given by local
recurrence-free survival. The other important outcomes were invasive local recurrence-free survival,
mastectomy-free survival, distant disease-free survival, overall survival, breast cancer mortality, and nonbreast cancer mortality.
We performed statistical analysis by using established methods.27 35 36 Hazard ratios were calculated by
using the Cox proportional hazard model with TARGIT-IORT as the numerator. We carried out censoring
appropriately for each outcome; for example, for survival outcomes, patients were censored at the time of
last follow-up, or the date of withdrawal. Kaplan-Meier graphs for these long term outcomes were
presented according to Pocock and colleagues,37 who recommended that the x axis should be extended
until 10-20% of patients are at risk of an event. This approach also ensures that any long term trends
(positive or negative) are not missed. We used the log rank test to compare differences between survival
functions and to obtain P values. All analyses were by intention to treat according to the randomisation
arm.
Each centre specified the cause of death. If the cause of death was specified as a non-breast cancer event
and no distant disease was recorded, it was defined as a non-breast cancer death. If the death was recorded
by the centre to be related to breast cancer, or as per convention, if breast cancer was present at the time of
death, or if the cause of death was recorded as unknown or uncertain, it was presumed to be a breast cancer
death.
The reference date for completeness was 2 May 2018, eight years after the first data lock. We considered
patients to have complete follow-up if they were seen for the specified duration of follow-up, if they were
seen within one year of the reference date, if they had died, or if they had withdrawn from the trial.
Because the last patient was randomised in 2012, the statistical analysis plan specified that the five year
follow-up would be considered complete if 95% of patients had complete follow-up. The plan also
specified that a 10 year follow-up would be considered complete if the patient had at least 10 years of
follow-up, had been seen within one year of the reference date, or had died or withdrawn from the study;
the 10 year follow-up would be considered complete if this was achieved by 90% of patients. The interim
analysis confirmed the safety of TARGIT-IORT, but the follow-up was relatively short. Therefore, the
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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independent data monitoring committee recommended that we continue recruitment while accruing the
required follow-up. There was no specific trial funding for individual centres and so return of follow-up
relied on individual investigators and the efforts of their teams, enthused by the trial centre team. The trial
statistician and the chief investigator produced reports of completeness of follow-up by using blinded
databases on a regular basis.
Once the thresholds set in the statistical analysis plan were reached, the database was unblinded for
analysis. The reference date for analysis was 3 July 2019, so that all events up until 2 July 2019 were
included for analysis. We used Stata version 16.0 for data compilation, validation, and analysis. The trial
steering and data monitoring committees each included a patient advocate as a member. Since the last
analysis, the trial oversight has been provided by an independent steering committee, appointed by the
Health Technology Assessment (HTA) programme of the National Institute of Health Research,
Department of Health and Social Care, UK, which also includes a patient as a member.
Patient and public involvement
Patients have been involved as members of the steering committee from the start. Patients were not
involved in the initial design of the study in 1999-2000, but they were involved from the time the trial
started. However, it was the serious concern about patients’ welfare that inspired the study design. The
pragmatic nature of this trial was designed to suit the patient’s perspective. The non-inferiority margin has
been validated with patient preference studies,28 29 30 which included asking patients about their priorities.
Patients were involved in recruitment to and conduct of the study as members of the steering committee
and on several occasions as commentators in the national press, TV, and radio. Patients assessed the
burden of intervention and the time required to participate. Unlike most other studies, participating in the
trial was the main pathway through which patients could access TARGIT-IORT and reduce the burden of
treatment (that is, they were likely to avoid external beam radiotherapy) in the 50% of the group
randomised to receive the TARGIT-IORT arm rather than the EBRT arm. A patient has been involved
during the development of the statistical analysis plan, interpretation of the results and writing of the
manuscript, and is an author of the paper.

Results
Between 24 March 2000 and 25 June 2012, 2298 patients were recruited to the study: 1140 patients were
randomised to receive risk adapted immediate TARGIT-IORT during lumpectomy and 1158 patients were
randomised to receive EBRT. Table 1 presents patient and tumour characteristics, which were well
matched between the randomised arms.
Complete follow-up to the prespecified level of 95% at five years was achieved by mid-2019. Figure 1
presents the flow and CONSORT (consolidated standards of reporting trials) diagrams. Figure 2 shows the
completeness of follow-up and illustrates that the observed follow-up is close to the expected follow-up in
each arm of the trial. The follow-up duration of the two arms did not differ (log rank P=0.22).
For the protocol specified primary outcome of non-inferiority at five years, we found that immediate
TARGIT-IORT was non-inferior to EBRT for local control (table 2): at five year complete follow-up, the
number of local recurrences was 24 (including six ductal carcinoma in situ) of 1140 (2.11%) for TARGITIORT versus 11 (including one ductal carcinoma in situ) of 1158 (0.95%) for EBRT. The difference in
local recurrence rate was 0.0116 (1.16%) and the 90% confidence interval was 0.0032 to 0.0199 (0.32% to
1.99%), establishing non-inferiority. Testing for non-inferiority by using five year Kaplan-Meier estimates
also confirmed that immediate TARGIT-IORT is non-inferior to EBRT (difference 1.21%, 90% confidence
interval 0.47% to 1.95%). We also confirmed non-inferiority when 95% confidence intervals were used,
and when per protocol analysis was performed with 90% and 95% confidence intervals. The number of
deaths was 42 of 1140 for TARGIT-IORT versus 56 of 1158 for EBRT.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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With long term follow-up (median 8.6 years, maximum 18.9 years, interquartile range 7.0-10.6), no
statistically significant difference was found between immediate TARGIT-IORT and EBRT for the
following outcomes: local recurrence-free survival (167 v 147 events, hazard ratio 1.13, 95% confidence
interval 0.91 to 1.41, P=0.28), invasive local recurrence-free survival (154 v 146 events, 1.04, 0.83 to 1.31,
P=0.70), mastectomy-free survival (170 v 175 events, 0.96, 0.78 to 1.19, P=0.82), distant disease-free
survival (133 v 148 events, 0.88, 0.69 to 1.12, P=0.30), overall survival (110 v 131 events, 0.82, 0.63 to
1.05, P=0.13), and breast cancer mortality (65 v 57 events, 1.12, 0.63 to 1.28, P=0.54). Mortality from
other causes was significantly lower (45 v 74 events, 0.59, 0.40 to 0.86, P=0.005). Analysis according to
treatment received found that local recurrence-free survival was no different from EBRT for the following
comparisons: TARGIT-IORT plus EBRT (n=241) versus EBRT (n=1065): hazard ratio 1.25, 95%
confidence interval 0.87 to 1.80, P=0.24; and TARGIT-IORT alone (n=786) versus EBRT (n=1065): 1.22,
0.95 to 1.57, P=0.11. We used Schoenfeld residuals to confirm that the proportionality assumption was not
violated (P=0.87 for local recurrence-free survival and P=0.81 for mortality). We also confirmed that there
was no heterogeneity between countries (efig 2). The number of patients who died with uncontrolled local
recurrence at the time of death was similar in the two arms of the trial (4/1140 for TARGIT-IORT and
5/1158 for EBRT, P=0.76). Table 3 gives the number of events and absolute event rates for local recurrence
and mortality up to five years, and beyond five years. Figure 3 shows the Kaplan-Meier curves and
figure 4 shows magnified Kaplan-Meier curves. Table 4 gives the causes of death.

Discussion
We based the TARGIT-IORT approach on the clinical observation that local recurrence after breast
conserving surgery, with or without whole breast irradiation, occurs predominantly within the index
quadrant.2 3 This observation holds true despite the fact that more than 60% of patients for whom breast
conservation is a treatment have foci of the disease outside the index quadrant.2 3 38 Using this observation
that most local recurrences occur in the index quadrant as the rationale for partial breast irradiation has
also been reiterated by subsequent investigators.15 17 19 The propensity of tumour recurrence in the index
quadrant could be owing to a tumour promoting effect of the microenvironment of the surgical wound,39
40 41 a risk that seems to be favourably influenced by TARGIT-IORT to the fresh tumour bed.39 41 42
Early results of using single dose TARGIT-IORT during lumpectomy were promising, and the treatment
was found to have advantages for the patient, such as convenience, reduced travel and personal costs,
improved quality of life, and fewer side effects.43 44 45 46 47 However, the international community has
been waiting for the long term follow-up outcomes before this approach is more widely adopted.
Statement of principal findings
The data presented here confirm that TARGIT-IORT is non-inferior to EBRT in terms of local control at
protocol specified five year complete follow-up (local recurrence risk 2.11% for TARGIT-IORT v 0.95%
for EBRT). Additionally, fewer deaths occurred with TARGIT-IORT. When we compared 1140 patients
treated with TARGIT-IORT with 1158 patients treated with EBRT, 13 more local recurrences and 14 fewer
deaths were reported. Figure 5 shows these raw data apportioned to 100 patients.
The Kaplan-Meier curves illustrate the long term results up to 12 years. These data confirm the
comparable effectiveness of TARGIT-IORT versus EBRT in terms of cancer control, with no difference in
local recurrence-free survival, invasive local recurrence-free survival, mastectomy-free survival, or distant
disease-free survival for at least 12 years from randomisation (fig 3).
Breast cancer specific mortality was similar for both arms, however far fewer deaths were reported from
causes other than breast cancer in the TARGIT-IORT arm. Even modern radiotherapy increases cardiac
and lung cancer mortality and the results are consistent with our previously published data48 49 50 51 52
3 4
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and a meta-analysis of randomised trials.53 54 Furthermore, the Kaplan-Meier curve for overall survival
for TARGIT-IORT always remains above EBRT, with the curves continuing to separate further well
beyond 10 years.
Strengths and weaknesses of the study
The pragmatic trial design is a major strength because the experimental arm simulated the potential future
real world practice. Patients would get TARGIT-IORT during their initial cancer operation, and if found to
have high risk factors, they would receive supplemental whole breast radiotherapy, making the results
more clinically applicable. The international setting and broad inclusion criteria mean that the results are
generalisable across relatively broad eligibility criteria and across various continents, even though centres
of excellence participated in the trial.
Patients were randomised between 2000 and 2012. Substantial effort along with close collaboration from
each centre enabled a high level of completeness of long term data. Consequently, another strength of the
TARGIT-A trial is that it has more long term follow-up data than other published trials comparing
individual techniques of partial breast irradiation with whole breast irradiation for invasive breast cancer (
table 5, fig 6). Additionally, figure 2 shows that actual follow-up time is close to the follow-up time
expected from the date patients were recruited, which means that substantial unknown data are unlikely.
The long duration and high level of completeness of follow-up mean that the trial outcome is reliable and
robust, and with 2298 participants, this trial is one of the largest in the field (table 5, fig 6). The trial was a
result of an academic insight and was investigator initiated and funded by the HTA programme of the UK
Department of Health and Social Care, rather than by industry sponsorship. The investigative team was
multidisciplinary and consisted of patients and experts in surgical oncology, radiation oncology, clinical
oncology, radiation physics, medical statistics, psycho-oncology, health economics, and clinical trial
management.
The ratio of ductal carcinoma in situ to invasive recurrence was higher in the TARGIT-IORT arm (12:32)
compared with the EBRT arm (1:19; table 3). One limitation of this study is that we do not know if this
finding is owing to overdiagnosis and ascertainment bias because of potentially more frequent use of
mammography in patients randomised to TARGIT-IORT, or if it is a real effect. However, this increase in
diagnosis of ductal carcinoma in situ in the TARGIT-IORT arm did not lead to a reduction in mastectomyfree survival.
Another limitation of the study was that we did not collect all the background risk factors for deaths from
non-breast cancer causes. However, the major risk factors for cardiovascular disease55 and malignant
disease56 that were formally collected during the trial were age and body mass index, and these factors
were distributed evenly between the two randomised arms. While smoking history and other common risk
factors were not collected, it is unlikely that their incidence would be imbalanced in such a large
randomised trial. Additionally, cause of death could not be determined for all patients. Therefore, patients
were deemed to have died of causes other than breast cancer only if the local principal investigator had
clearly specified that the cause of death was not breast cancer and breast cancer was not present, and only
when there was no record of the patient having had any relapse of breast cancer.
The perspective in relation to other studies investigating partial breast irradiation
Partial breast irradiation was heralded as a new standard12 at the time of the first publication of the
TARGIT-A trial.11 Several other supporting trials have since been published, including the ELIOT trial,15
and studies examining brachytherapy,18 and partial breast EBRT.17 19 The TARGIT-A and ELIOT trials
differ considerably in their inclusion criteria, and most importantly, have entirely different surgical and
radiotherapeutic techniques, and so are not comparable. A Cochrane meta-analysis published in 201657
included all diverse methods of partial breast irradiation, but could not make definitive conclusions
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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because of data limitations. Our own meta-analysis that only examined mortality (initially published in
2016 and updated in 2018)53 54 found that partial breast irradiation has no impact on breast cancer
mortality but reduces non-breast cancer mortality and overall mortality.
In general, the other trials of partial breast irradiation with EBRT have included patients with cancer with
considerably better prognosis. For example, when we compared the IMPORT-Low trial19 patient
population with that of the TARGIT-A trial, 3% versus 22% had node positivity, and 9% versus 20% had
grade 3 tumours. Furthermore, this new analysis of long term data suggests that the greater proportion of
patients with higher risk disease has not jeopardised the outcome in the TARGIT-A trial. We recommend
that risk adapted TARGIT-IORT should be used in patients who would have been eligible for the TARGITA trial. Partial breast irradiation with EBRT still requires up to three weeks of daily radiation with about 16
hospital visits.19 Although newer brachytherapy or some intensity modulated radiotherapy regimens could
be completed in 10 fractions over five days, these trials had much smaller numbers of patients (108158 and
26017 patients with five years of follow-up compared with 2048 in immediate TARGIT-A v EBRT; table 5,
fig 6). Most of these techniques have adverse physical, social, financial,59 60 61 and environmental
impacts,43 and do not substantially reduce the heavy workload of radiotherapy departments. Conversely,
TARGIT-IORT delivered during the operation enables four fifths of patients to avoid visiting the
radiotherapy centre at all.
Meaning of the study and implications for clinicians and policy makers
The long term results of this trial have shown that risk adapted single dose TARGIT-IORT given during
lumpectomy can effectively replace the mandatory use of several weeks of daily postoperative whole
breast radiotherapy in patients with breast cancer undergoing breast conservation. Crucially, 80% of
patients required no additional radiotherapy after TARGIT-IORT. Additionally, TARGIT-IORT reduced
non-breast cancer mortality. The advantage to the patient of avoiding postoperative radiotherapy could be
considered obvious. Furthermore, formal studies have also been performed and have reported quality of
life and patient reported outcomes such as cosmesis, breast related quality of life, and breast pain to be
superior with TARGIT-IORT in the first five years.44 45 46 47 Additionally, patients prefer this approach
even when faced with a potentially higher local recurrence risk.28 29 30 Moreover, 80% of patients, many
of whom live a considerable distance from the radiotherapy centre,43 57 avoid the need for daily hospital
visits for three to six weeks, which would be required for established radiotherapy techniques. For such
patients, TARGIT-IORT provides the opportunity for breast conservation rather than being obliged to
choose mastectomy.62 Even as recently as 2015, in a modern urban community (New Jersey, US), patients
who lived more than 9.2 miles from the radiation facility (or more than 19 minutes away by car) compared
with less than 9.2 miles away were 36-44% more likely to receive a mastectomy than breast
conservation.63
Another important advantage is the major cost savings for the health services reported in previously
published studies of health economics of the TARGIT-A trial.59 60 61 All these factors are important when
considering a change of policy and determining which treatments should be funded at the national level by
organisations such as the NHS in the UK and Medicare or Medicaid in the US. While the payers will save
scarce healthcare resources by using TARGIT-IORT, the providers will also want to use this approach
when the payment model is changed to be value based rather than activity based.
Another important aspect is the well recognised phenomenon of overdiagnosis of breast cancer because of
systematic population screening. This is a difficult problem because the potential of reduced breast cancer
mortality needs to be balanced against the definite harms of overtreatment of women who might not have
had a diagnosis of breast cancer if it were not for the screening programme. TARGIT-IORT could largely
reduce the burden of treatment on such patients, and has been recommended by the Marmot committee.64
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10/34

10/21/2020

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT)…

Implications for patients
When these results are expressed from the patient’s perspective, without any definitions of non-inferiority,
they would read as follows: “I understand from your explanation that if I choose to have intraoperative
radiotherapy during my lumpectomy operation, the whole treatment will probably be completed in one go.
I understand that the chance of avoiding a full course of traditional whole breast radiotherapy is about
80%, which requires several daily visits to complete. The results of this study have reassured me that
choosing intraoperative radiotherapy doesn’t reduce my long term chances of survival or keeping my
breast, and remaining cancer free. You have also told me that there will be fewer long term side effects, a
better quality of life and that the cosmetic result is likely to be better. I am also reassured to learn that this
treatment does in fact reduce my chance of death from causes other than breast cancer.”
Patients are entitled to choose which approach is right for them, based on effectiveness, convenience,
personal cost, quality of life, and side effects. To allow a truly informed patient to make the choice
between a risk adapted TARGIT-IORT policy and conventional EBRT, we need to supply the data using
absolute numbers in an easily accessible and comprehensible way.65 A pictographic display (fig 4), based
on the raw numerical data, is a transparent and accurate way of supporting the patient to make an informed
choice.
We believe that the long term data presented in this paper, together with many benefits for the patient,
provide compelling evidence in favour of TARGIT-IORT as an effective alternative for this large group of
patients with early breast cancer who are suitable for breast conservation. Ultimately the treatment patients
receive should be their choice and they should be provided with the data in a format which is transparent,
straightforward, and easily understood.
Future and ongoing work
Additional work based on these results includes subgroup analysis, an analysis of local recurrence as a
hazard for distant disease, and an analysis exploring the mechanisms behind the differences in non-breast
cancer mortality seen in the trial. We will also present a web based tool to allow clinicians to use the risk
adapted approach. The inputs for this tool include individual patient data, and the output gives the
probability of a patient needing supplemental EBRT after TARGIT-IORT within the TARGIT-A trial.
Further investigation into the nature of local recurrences will include molecular markers and the location
within the breast.
In the extended follow-up of the TARGIT-A trial (TARGIT-Ex; funded by the HTA programme of the
National Institute for Health Research, Department of Health and Social Care in the UK, HTA 14/49/13)
we will use new methods such as direct patient contact and linkage with the Office for National Statistics.
We are also currently inviting women who would fall outside the eligibility criteria of the TARGIT-A trial
to participate in the TARGIT-B(oost) trial (funded by HTA 10/104/07), already opened in 36 centres
internationally, which is comparing TARGIT-IORT as a tumour bed boost with EBRT boost in younger
women or women who have a higher risk of disease to test for superiority in terms of local control and
survival.
What is already known on this topic
When early breast cancer is treated with breast conserving surgery (lumpectomy) rather than
mastectomy, adjuvant whole breast postoperative external beam radiotherapy, given as multiple
doses over several days, reduces the risk of local recurrence
Restricting radiotherapy to only the area around the tumour by using intraoperative radiotherapy
has the benefits of precision and immediacy, and avoids the inevitable delay in starting
postoperative radiotherapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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Early results of using single dose targeted intraoperative radiotherapy (TARGIT-IORT) during
lumpectomy indicate this approach has many advantages for the patient, such as less travelling
for treatment, improved quality of life, and fewer side effects
What this study adds
The results of the TARGIT-A trial show that TARGIT-IORT has similar long term local control
and cancer survival outcomes to whole breast radiotherapy
Mortality from other causes was lower in the TARGIT-IORT arm
Single dose TARGIT-IORT during lumpectomy should be accessible to healthcare providers and
discussed with patients when surgery for breast cancer is being planned
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Dissemination to participants and related patient and public communities: We plan to widely disseminate
the published paper. We shall use all modern media and engage patients and our own institutional public
relations departments.
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Table 1
Patient and tumour characteristics in the TARGIT-IORT and EBRT arms
Characteristics

TARGIT-IORT (n=1140) EBRT (n=1158)

Age (years)
≤50

117 (10.3)

99 (8.6)

51-60

362 (31.8)

375 (32.4)

61-70

481 (42.2)

524 (45.3)

>70

180 (15.8)

160 (13.8)

Normal (<25)

408 (41.0)

420 (42.2)

Overweight (25-29.9)

375 (37.7)

329 (33.1)

Obese (≥30)

212 (21.3)

246 (23.7)

Unknown

145 (12.7)

163 (14.1)

40 (25-65)

40 (24-70)

Body mass index

Specimen weight (g)
Median (interquartile range)

Pathological tumour size (mm; P=0.70)
≤10

369 (33.1)

370 (33.1)

11-20

571 (51.2)

557 (49.9)

>20

176 (15.8)

190 (17.0)

24 (2.1)

41 (3.5)

1

275 (24.5)

286 (25.6)

2

621 (55.4)

615 (55.0)

3

226 (20.1)

217 (19.4)

18 (1.6)

40 (3.5)

1007 (89.4)

993 (88.2)

Ductal carcinoma in situ only

54 (4.8)

60 (5.3)

Invasive

65 (5.8)

73 (6.5)

Unknown

14 (1.2)

32 (2.8)

Re-excision

76 (6.7)

97 (8.4)

Unknown
Grade

Unknown
Margin
Free

Lymphovascular invasion

Open in a separate window
EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy.
Data are numbers (percentages). For percentage calculation, the denominator for unknown percentages is the total
number randomised (1140 and 1158) and the denominator for each category is the total number of known patients. No
imbalance was found for any of these characteristics between the two randomised arms.
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Fig 1

Open in a separate window
Flowchart outlining TARGIT-A recruitment and CONSORT (consolidated standards of reporting trials) diagram.
*Difference in number withdrawn was statistically significant (P=0.002). †Crossovers: 65/1140 (5.7%) allocated
TARGIT-IORT received EBRT, and 22/1158 (1.9%) allocated EBRT received TARGIT-IORT. ‡1027/1140 (91%)
allocated TARGIT-IORT and 1065/1158 (92%) allocated EBRT received allocated treatment. §As per protocol, 241/1140
(21.1%) patients allocated TARGIT-IORT received EBRT after TARGIT-IORT. EBRT=external beam radiotherapy;
TARGIT-IORT=targeted intraoperative radiotherapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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Fig 2

Completeness of follow-up. Curves for actual follow-up and how close they are to curves for expected follow-up.
Expected is presumed equal to actual if patients have withdrawn or died. No significant difference in follow-up duration
between TARGIT-IORT and EBRT (log rank P=0.22). EBRT=external beam radiotherapy; TARGIT-IORT=targeted
intraoperative radiotherapy
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Table 2
Analysis of non-inferiority by using binomial proportions and Kaplan-Meier estimates
Analysis

TARGIT-IORT

EBRT

2.11

0.95

Intention-to-treat analysis (n=1140; n=1158)
Binomial proportions of five year local recurrence
Difference (90% CI; 95% CI)
Kaplan-Meier estimates of local recurrence at five year complete follow-up (SE)
Difference (90% CI; 95% CI)

1.16 (0.32 to 1.99; 0.15 to 2.16)
2.23 (0.45)

1.02 (0.31)

1.21 (0.47 to 1.95; 0.33 to 2.09)

Per protocol analysis (n=1027; n=1065)
Binomial proportions of five year local recurrence
Difference (90% CI; 95% CI)
Kaplan-Meier estimates of local recurrence at five year complete follow-up (SE)
Difference (90% CI; 95% CI)

2.24

0.94

1.30 (0.40 to 2.20; 0.23 to 2.38)
2.36 (0.49)

0.99% (0.31)

1.37 (0.56 to 2.18; 0.41 to 2.33)

EBRT=external beam radiotherapy; SE=standard error; TARGIT-IORT=targeted intraoperative radiotherapy.
The protocol specified that the non-inferiority test should be performed with a prespecified margin of 2.5% at five
years. The statistical analysis plan stated that analysis of non-inferiority should be performed by calculating
difference in binomial proportion of local recurrence rates at five years, and that non-inferiority would be considered
as established if upper 90% confidence interval of difference did not cross 0.025 (2.5%). Local recurrence risk and
difference in this risk are depicted as absolute percentage (eg, difference in risk of 0.0116 is depicted as 1.16%). For
completeness, test for non-inferiority was performed by using five year Kaplan-Meier estimates of local recurrence
and per protocol analysis. Results show that TARGIT-IORT remains non-inferior to EBRT.
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Table 3
Number of events and absolute event rates (percentages) of local recurrence and death
Local recurrence and death

TARGIT-IORT

EBRT (n=1158)

(n=1140)
≤5 years >5-19 years

≤5

>5-19

years

years

Local recurrence was invasive with or without DCIS

15 (1.3)

17 (1.5)

9 (0.8)

10 (0.9)

Local recurrence was only DCIS

6 (0.5)

6 (0.6)

1 (0.1)

0

Local recurrence type was unknown* (assumed as invasive for

3 (0.3)

13 (1.1)

1 (0.1)

3 (0.3)

42 (3.7)

68 (5.9)

56 (4.8)

75 (6.5)

analysis)
No of deaths

DCIS=ductal carcinoma in situ; EBRT=external beam radiotherapy; SE=standard error; TARGIT-IORT=targeted
intraoperative radiotherapy.
There is complete follow-up at five years and maximum follow-up at 18.9 years. This table gives the number of
events up to five years and beyond five years. The protocol specified that number of local recurrences (all types) at
five years should be used for calculation of non-inferiority at 2.5% margin and all types of local recurrences were
included.
*

Local recurrence of unknown type was included as invasive local recurrence in long term invasive local recurrencefree survival analysis.
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Fig 3

Open in a separate window
Kaplan-Meier estimates and curves for the following outcomes for TARGIT-IORT versus EBRT in the TARGIT-A trial:
local recurrence-free survival, invasive local recurrence-free survival, mastectomy-free survival, distant disease-free
survival, breast cancer specific survival, non-breast cancer survival, and overall survival. Figures under titles are hazard
ratios (95% confidence intervals) and log rank test P values. EBRT=external beam radiotherapy; TARGIT-IORT=targeted
intraoperative radiotherapy
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Fig 4

Open in a separate window
Kaplan-Meier curves showing differences in breast cancer mortality, non-breast cancer mortality, and overall mortality in
TARGIT-A trial for TARGIT-IORT v EBRT. Figures under titles are hazard ratios (95% confidence intervals) and log rank
test P values. EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy
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Table 4
Number of deaths from breast cancer and other causes
Causes of death

TARGIT-IORT EBRT Total

Death from breast cancer
Breast cancer*

35

32

—

Breast cancer present at time of death*

6

7

—

Unknown or uncertain*

24

18

—

Total breast cancer deaths

65

57

122

Other cancers

15

21

—

Cardiovascular causes

8

20

—

Pulmonary causes

4

9

—

Other causes/exact cause not given

18

24

—

Total non-breast cancer deaths

45

74

119

Total

110

131

241

Death from other causes*

EBRT=external beam radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy.
*

Case record form for death completed by centre stipulated classification of deaths as one of the following: breast
cancer; breast cancer present at time of death including previously reported distant disease; not breast cancer and
breast cancer not present; unknown or uncertain. As per convention, only deaths classified as not breast cancer and
breast cancer not present were classified as non-breast cancer deaths.
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Fig 5

Open in a separate window
Pictogram showing outcomes in TARGIT-A trial of TARGIT-IORT v EBRT for breast cancer. Complete follow-up is
available for five years. Each dot represents a patient. Absolute numbers of patients who had local recurrences, distant
disease, and died (TARGIT-IORT: 24/1140 local recurrences, 34/1140 distant disease, and 42/1140 deaths; EBRT: 11/1158
local recurrences, 31 distant disease, and 56/1158 deaths) are apportioned per 100 patients for each treatment type. At five
years, one more local recurrence and one less death were reported per 100 patients. EBRT=external beam radiotherapy;
TARGIT-IORT=targeted intraoperative radiotherapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/?report=printable
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Table 5
Number of patients at risk at various time points in published randomised trials that use different
techniques of partial breast irradiation for invasive breast cancer
Study

Total

No of patients at risk*
5

6

7

8

9

10

11

12

years

years

years

years

years

years

years

years

2298

2048

1967

1736

1361

1035

749

587

295

1153

1097

1068

967

781

582

364

227

146

1305

—

676

—

305

—

29

—

—

Florence (IMRT; 5 days daily
17
doses)

520

260

—

—

—

—

—

—

GEC-ESTRO (2×5 days
18
brachytherapy)

1184

1081

829

—

—

—

—

—

—

1343

1109

661

239

—

—

—

—

—

258

—

231

—

113

—

134

—

57

2193

—

1915

—

1335

—

929

—

—

811

—

708

—

494

—

344

—

—

1754

1593

1548

1344

986

654

—

—

—

174

130

120

106

88

64

40

27

16

708

400

250

127

40

—

—

—

—

TARGIT-A (immediate TARGITIORT)
TARGIT-A (delayed TARGIT-IORT)
15
ELIOT (IORT)

19
IMPORT-Low (3 weeks EBRT)
16
Budapest (7 days brachytherapy)
NSABP-B39 3DCRT/IMRT (10# 8
20
days†)
20
NSABP-B39 Balloon (10# 8 days†)
RAPID 3DCRT/IMRT (10# 8
21
days†)
14
Leeds (EBRT 28 days)
10
Christie (EBRT 10 days)

10# 8 days=10 fractions in eight days; EBRT=external beam radiotherapy; IMRT=intensity modulated radiotherapy;
IORT=intraoperative radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy.
Values are shown graphically in figure 6. Proportion of invasive cancer: 100% for TARGIT-A, ELIOT, IMPORTLow, Budapest, Leeds, and Christie, 73% for NSABP-B39, 82% for RAPID, 89% for Florence, and 95% for GECESTRO.
*

Follow-up durations shown in Kaplan-Meier plots.
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Fig 6

Amount of data in randomised trials of different techniques of partial breast irradiation for invasive breast cancer. 10# 8
days=10 fractions in eight days; EBRT=external beam radiotherapy; IMRT=intensity modulated radiotherapy;
IORT=intraoperative radiotherapy; TARGIT-IORT=targeted intraoperative radiotherapy
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